Beigene, the First Pharma Company to Receive FDA’s Approval for Brukinsa
On November 14, 2019, the U.S. Food and Drug Administration gave approval to BeiGene Ltd's lymphoma treatment, Brukinsa. BeiGene is a Chinese biopharmaceutical company that focused on cancer treatments. The treatment "Brukinsa" has been tested on 118 patients with...
China’s National Reimbursement Drug List (NRDL)
What is NRDL? The National Reimbursement Drug List (NRDL) was introduced in 2000 to support medical healthcare and providing patients with basic medical treatments. Between 2000 and 2017, the NRDL has been updated twice, but the reimbursement process is poor. The...
China Introduces Structural Changes to Pharmaceutical Regulations
Beginning of Changes China revised its pharmaceutical regulations by releasing the second draft of the Drug Administration Law of the People's Republic of China (DAL) to the Committee of the National People's Congress of China (NPC) for discussion. The first draft...
FDA Reducing Price of New Drugs Through Drug Competition Action Plan
The Theory At the American Society of Clinical Oncology (ASCO), FDA Commissioner Dr. Scott Gottlieb introduced the Drug Competition Action Plan, which aims to lower new drug pricing by increasing generic (alternative) drug competition in the pharmaceutical market....
China’s New Human Genetic Resources Policy
CHINA’S NEW HUMAN GENETIC RESOURCES POLICY New Regulation Underway On May 28, 2019, the Chinese government published new regulations on the management of Human Genetic Resources (HGRs). The main objective of the government is to observe all HGR- related activities,...